Drugs / KPG-818
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04283097 | Sep 2021 → Dec 2024 | hematopoietic and lymphoid cell neoplasm | Kangpu Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03949426 | May → Sep 2019 | systemic lupus erythematosus | Kangpu Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04643067 Comparator | Jun 2021 → Aug 2023 | systemic lupus erythematosus | Kangpu Biopharmaceuticals, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-11-18 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu to Present Latest Study Results of Epaldeudomide (KPG-818) at the 67th ASH Annual Meeting kangpugroup.com ↗
Epaldeudomide demonstrated favorable pharmacokinetic characteristics, good safety and tolerability, and promising efficacy. |
| 2025-04-28 | Kangpu Biopharmaceuticals, Ltd. | Regulatory Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE kangpugroup.com ↗
Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneous manifestations of systemic lupus erythematosus (SLE). |
| 2025-02-25 | Kangpu Biopharmaceuticals, Ltd. | Regulatory Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma kangpugroup.com ↗
Kangpu Biopharmaceuticals, Ltd. (“Kangpu”) today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory multiple myeloma (RRMM). |
| 2024-09-20 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu Completed Bridging Clinical Study of KPG-818 in China kangpugroup.com ↗
Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China. |
| 2024-06-11 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024 kangpugroup.com ↗
The results showed that KPG-818 0.15 mg and 0.6 mg were generally well tolerated after 12 weeks of drug administration. |
| 2024-02-19 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn's Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress) kangpugroup.com ↗
In preclinical studies, KPG-818 demonstrated potent therapeutic efficacy in mouse model of Crohn's disease. |
| 2022-11-25 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu Presented Phase Ib Results of KPG-818 in SLE at ACR Convergence 2022 kangpugroup.com ↗
Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced today that it has presented the Phase Ib results of KPG-818 in Systemic Lupus Erythematosus (SLE) at the 2022 American College of Rheumatology (ACR) Annual Meeting recently held in Philadelphia, Pennsylvania. |
| 2019-10-11 | Kangpu Biopharmaceuticals, Ltd. | Results Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the US kangpugroup.com ↗
Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted in the United States. |
All press releases naming this drug 11 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KPG-818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03949426 ↗ |
| Route | Oral | “for oral administration” NCT03949426 ↗ |